# Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease

> **NCT01453569** · PHASE2 · COMPLETED · sponsor: **Shanghai Greenvalley Pharmaceutical Co., Ltd.** · enrollment: 255 (actual)

## Conditions studied

- Alzheimer Disease
- Cognitive Impairment

## Interventions

- **DRUG:** Sodium oligo-mannurarate 600mg
- **DRUG:** Sodium oligo-mannurarate 900mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01453569
- **Lead sponsor:** Shanghai Greenvalley Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2015-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453569, "Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01453569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*